Smear-Negative Multidrug-Resistant Tuberculosis a Significance Hidden Problem for MDR-TB Control: An Analysis of Real World Data

Jingming Liu, Wei Wang, Jing Xu, Mengqiu Gao, Chuanyou Li

Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Rsearch Institute, Beijing, China.
Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing, China.

DOI: 10.4236/jtr.2014.22011                

Abstract

Purpose: The drug resistance pattern in tuberculosis (TB) is still under investigated. We analyzed the clinical data from the patients with smear positive TB and applied the model to predict the patients with smear-positive TB. Materials and Methods: Medical records information of 6977 cases was included from 11,950 inpatients from January 2009 to November 2013. The cases data were divided into a training set, test set and prediction set. Logistic regression analysis was applied to the training set data to establish a prediction classification model, the effect of which was then evaluated using the test set by receiver operating characteristic (ROC) analysis. The model was then applied to the prediction set to identify incidence of snMDR-TB. Results: Sixteen factors which correlate with MDR-TB-including frequency of hospitalization, province of origin, anti-TB drugs, and complications, were identified from the comparison between SP-TB and spMDR-TB. The area under the ROC curve (AUC) of the prediction model was 0.752 (sensitivity = 61.3%, specificity = 83.3%). The percentage of all inpatients with snMDR-TB (snMDR-TB/Total) was 28.7% ± 0.02%, while that of all SN-PTB with snMDR-TB (snMDR-TB/SN-PTB) was 26.5% ± 0.03%. The ratio of snMDR-TB to MDR-TB (snMDR-TB/MDR-TB) was 2.09 ± 0.33. Conclusion: snMDR-TB as an important source of MDR-TB is a significant hidden problem for MDR-TB control and can be identified by the prediction model. A kind of vicious circle with a certain delay effect exists between snMDR-TB and MDR-TB. To better control MDR-TB, it is necessary to pay greater attention to snMDR-TB, conduct further research and develop targeted therapeutic strategies.

Keywords

MDR-TB, snMDR-TB, SN-PTB, Real World Data

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	WHO (2012) Global Tuberculosis Report 2012. World Health Organization Report, 1.
[2]	Walusimbi, S., Bwanga, F., De Costa, A., Haile, M., Joloba, M. and Hoffner, S. (2013) Meta-Analysis to Compare the Accuracy of Genexpert, Mods and the WHO 2007 Algorithm for Diagnosis of Smear-Negative Pulmonary Tuberculosis. BMC Infectious Diseases, 13, 507. http://dx.doi.org/10.1186/1471-2334-13-507
[3]	Chinese Medical Association Chinese Society for Tuberculosis (2001) Treatment and Diagnosis of Tuberculosis Guidelines. Chinese Journal of Tuberculosis and Respiratory Diseases, 24, 5-9.
[4]	Getahun, H., Harrington, M., O’Brien, R. and Nunn, P. (2007) Diagnosis of Smear-Negative Pulmonary Tuberculosis in People with HIV Infection or Aids in resource-Constrained Settings: Informing Urgent Policy Changes. Lancet, 369, 2042-2049. http://dx.doi.org/10.1016/S0140-6736(07)60284-0
[5]	Robert, T.H., James, T.G. and Witten, D. (2013) An Introduction to Statistical Learning with Applications in R.
[6]	R Core Team. R: A Language and Environment for Statistical Computing (2013) R Foundation for Statistical Computing. Vienna.
[7]	Langendam, M.W., Tiemersma, E.W., van der Werf, M.J. and Sandgren, A. (2013) Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review. PLoS One, 8, Article ID: e53599. http://dx.doi.org/10.1371/journal.pone.0053599
[8]	WHO (2010) Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva.
[9]	Zhao, Y.L., Xu, S.F., Wang, L.X., Chin, D.P., Wang, S.F., Jiang, G.L., Xia, H., Zhou, Y., Li, Q., Ou, X.C., Pang, Y., Song, Y.Y., Zhao, B., Zhang, H.T., He, G.X., Guo, J. and Wang, Y. (2012) National Survey of Drug-Resistant Tuberculosis in China. The New England Journal of Medicine, 366, 2161-2170. http://dx.doi.org/10.1056/NEJMoa1108789
[10]	Solomon, S., Balakrishnan, P., Vignesh, R., Waldrop, G., Solomon, S.S., Murugavel, K.G., Kumarasamy, N., Yepthomi, T., Poongulali, S., Swathirajan, C.R., Sreenivasan, V., Chandrasekar, C., Suriakumar, J., Mahilmaran, A., Manoharan, G. and Moore, D.A.J. (2013) A Rapid and Low-Cost Microscopic Observation Drug Susceptibility Assay for Detecting TB and MDR-TB among Individuals Infected by HIV in South India. Indian Journal of Medical Microbiology, 31, 130-137. http://dx.doi.org/10.4103/0255-0857.115225
[11]	Alsaad, N., Wilffert, B., van Altena, R., de Lange, W.C.M., van der Werf, T.S., Kosterink, J.G.W. and Alffenaar, J.W.C. (2014) Potential Antimicrobial Agents for the Treatment of MDR-TB. European Respiratory Journal, 43, 884-897. http://dx.doi.org/10.1183/09031936.00113713
[12]	Sturdy, A., Goodman, A., Jos, R.J., Loyse, A., O’Donoghue, M., Kon, O.M., Dedicoat, M.J., Harrison, T.S., John, L., Lipman, M. and Cooke, G.S. (2011) Multidrug-Resistant Tuberculosis (MDR-TB) Treatment in the UK: A Study of Injectable Use and Toxicity in Practice. Journal of Antimicrobial Chemotherapy, 66, 1815-1820. http://dx.doi.org/10.1093/jac/dkr221
[13]	Fraser, H.S.F., Habib, A., Goodrich, M., Thomas, D., Blaya, J.A., Fils-Aime, J.R., Jazayeri, D., Seaton, M., Khan, A.J., Choi, S.S., Kerrison, F., Falzon, D. and Becerra, M.C. (2013) E-health Systems for Management of MDR-TB in Resourcepoor Environments: A Decade of Experience and Recommendations for Future Work. Studies in Health Technology and Informatics, 192, 627-631.
[14]	Kritski, A.L., Marques, M.J., Rabahi, M.F., Vieira, M.A., Werneck-Barroso, E., Carvalho, C.E., de N. Andrade, G., Bravo de Souza, R., Andrade, L.M., Gontijo, P.P. and Riley, L.W. (1996) Transmission of Tuberculosis to Close Contacts of Patients with Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 153, 331-335. http://dx.doi.org/10.1164/ajrccm.1531.8542139
[15]	Simon Schaaf, H., Gie, R.P., Kennedy, M., Beyers, N., Hesseling, P.B. and Donald, P.R. (2002) Evaluation of Young Children in Contact with Adult Multidrug-Resistant Pulmonary Tuberculosis: A 30-Month Follow-Up. Pediatrics, 109, 765-771.
[16]	Attamna, A., Chemtob, D., Attamna, S., Fraser, A., Rorman, E., Paul, M. and Leibovici, L. (2009) Risk of Tuberculosis in Close Contacts of Patients with Multidrug Resistant Tuberculosis: A Nationwide Cohort. Thorax, 64, 271. http://dx.doi.org/10.1136/thx.2008.100974
[17]	van der Werf, M.J., Langendam, M.W., Sandgren, A. and Manissero, D. (2012) Lack of Evidence to Support Policy Development for Management of Contacts of Multi-drug-Resistant Tuberculosis Patients: Two Systematic Reviews. International Journal of Tuberculosis and Lung Disease, 16, 288-296. http://dx.doi.org/10.5588/ijtld.11.0437
[18]	Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J.P., Dai, Z., Wang, J.F., Zhang, Z.Y., Lu, S.H., Huang, X.W., Wang, Z., Qiu, S.J., Wang, X.Y., Yang, G.H., Sun, H.C., Tang, Z.Y., Wu, Y., Zhu, H.G. and Fan, J. (2011) Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma. Journal of Clinical Oncology, 29, 4781-4788.
[19]	Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L.F., Galasko, D.R., Jutel, M., Karydas, A., Kaye, J.A., Leszek, J., Miller, B.L., Minthon, L., Quinn, J.F., Rabinovici, G.D., Robinson, W.H., Sabbagh, M.N., So, Y.T., Larry Sparks, D., Tabaton, M., Tinklenberg, J., Yesavage, J.A., Tibshirani, R. and Wyss-Coray, T. (2007) Classification and Prediction of Clinical Alzheimer’s Diagnosis Based on Plasma Signaling Proteins. Nature Medicine, 13, 1359-1362. http://dx.doi.org/10.1038/nm1653
[20]	Kumar, V. and Wu, X.D. (2009) The Top Ten Algorithms in Data Mining. CRC Press, Boca Raton.
[21]	Chen, S.H., Huai, P.C., Wang, X.M., Zhong, J.M., Wang, X.T., Wang, K., Wang, L.X., Jiang, S.W., Li, J., Peng, Y. and Ma, W. (2013) Risk Factors for Multidrug Resistance among Previously Treated Patients with Tuberculosis in Eastern China: A Case-Control Study. International Journal of Infectious Diseases, 17, e1116-e1120. http://dx.doi.org/10.1016/j.ijid.2013.06.006
[22]	Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., Hoffner, S., Rusovich, V., Dadu, A., de Colombani, P., Dara, M., van Gemert, W. and Zignol, M. (2013) Multidrug-Resistant Tuberculosis in Belarus: The Size of the Problem and Associated Risk Factors. Bulletin of the World Health Organization, 91, 36-45. http://dx.doi.org/10.2471/BLT.12.104588
[23]	Zetola, N.M., Modongo, C., Kip, E.C., Gross, R., Bisson, G.P. and Collman, R.G. (2012) Alcohol Use and Abuse among Patients with Multidrug-Resistant Tuberculosis in Botswana. International Journal of Tuberculosis and Lung Disease, 16, 1529-1534. http://dx.doi.org/10.5588/ijtld.12.0026
[24]	Diand, S., Sangar, L., Kouanda, S., Dingtoumda, B.I., Mourfou, A., Oudraogo, F., Sawadogo, I., Nbi, B., Gueye, A., Sawadogo, L.T. and Traor, A.S. (2009) Risk Factors for Multidrug-Resistant Tuberculosis in Four Centers in Burkina Faso, West Africa. Microbial Drug Resistance, 15, 217-221. http://dx.doi.org/10.1089/mdr.2009.0906
[25]	Otero, L., Krapp, F., Tomatis, C., Zamudio, C., Matthys, F., Gotuzzo, E., Van der Stuyft, P. and Seas, C. (2011) High Prevalence of Primary Multidrug Resistant Tuberculosis in Persons with No Known Risk Factors. PLoS ONE, 6, Article ID: e26276. http://dx.doi.org/10.1371/journal.pone.0026276
[26]	Vadwai, V., Shetty, A., Soman, R. and Rodrigues, C. (2012) Determination of Risk Factors for Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Treatment Failure Patients. Scandinavian Journal of Infectious Diseases, 44, 48-50. http://dx.doi.org/10.3109/00365548.2011.611169
[27]	Falzon, D., Jaramillo, E., Schnemann, H.J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J.A., Daley, C.L., Duncombe, C., Fitzpatrick, C., Gebhard, A., Getahun, H., Henkens, M., Holtz, T.H., Keravec, J., Keshavjee, S., Khan, A.J., Kulier, R., Leimane, V., Lienhardt, C., Lu, C., Mariandyshev, A., Migliori, G.B., Mirzayev, F., Mitnick, C.D., Nunn, P., Nwagboniwe, G., Oxlade, O., Palmero, D., Pavlinac, P., Quelapio, M.I., Raviglione, M.C., Rich, M.L., Royce, S., Rsch-Gerdes, S., Salakaia, A., Sarin, R., Sculier, D., Varaine, F., Vitoria, M., Walson, J.L., Wares, F., Weyer, K., White, R.A. and Zignol, M. (2011) Who Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. European Respiratory Journal, 38, 516-528. http://dx.doi.org/10.1183/09031936.00073611
[28]	Espinal, M.A., Laserson, K., Camacho, M., Fusheng, Z., Kim, S.J., Tlali, R.E., Smith, I., Suarez, P., Antunes, M.L., George, A.G., Martin-Casabona, N., Simelane, P., Weyer, K., Binkin, N. and Raviglione, M.C. (2001) Determinants of Drug-Resistant Tuberculosis: Analysis of 11 Countries. International Journal of Tuberculosis and Lung Disease, 5, 887-893.
[29]	Joint United Nations Programme on HIV/AIDS World Health Organization Ministry of Health, People’s Republic of China (2011) 2011 Estimates for the HIV/AIDS Epidemic in China. Ministry of Health China, UNAIDS, WHO.
[30]	Ahui, B.J.M., Horo, K., Bakayoko, A.S., Kouassi, A.B., Anon, J.C., Brou-Gode, V.C., Koffi, M.O., Itchy, M.V., N’gom, A.S., N’Goran, N.B. and Aka-Danguy, E. (2013) Evaluation of Multidrug-Resistant Tuberculosis Treatment in Ivory Coast from 2008 to 2010. Revue de Pneumologie Clinique, 69, 315-319. http://dx.doi.org/10.1016/j.pneumo.2013.08.002
[31]	Korzeniewska-Kosea, M. (2013) Tuberculosis in Poland in 2011. Przeglad Epidemiologiczny, 67, 277-281, 375-378.
[32]	Law, W.S., Yew, W.W., Chiu Leung, C., Kam, K.M., Tam, C.M., Chan, C.K. and Leung, C.C. (2008) Risk Factors for Multidrug-Resistant Tuberculosis in Hong Kong. International Journal of Tuberculosis and Lung Disease, 12, 1065-1070.